Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must give a written, signed and dated informed consent~* Chronic atopic dermatitis present for at least 1 year before Baseline~* Moderate to severe atopic dermatitis defined as per EASI, IGA and BSA.~* Documented recent history (within 6 months before the screening visit) of inadequate response to treatment with topical medications or for whom topical treatments are otherwise medically inadvisable~* Candidate for systemic treatment~Exclusion Criteria:~* Any skin disease that would confound the diagnosis or evaluation of atopic dermatitis disease activity~* Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days or until the expected pharmacodynamic effect has returned to baseline, whichever is longer.~* History of hypersensitivity to any of the study drug constituents or to drugs of similar chemical classes.~* Participation in prior ZPL389 studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): Placebo
- ZPL389 3mg (Type: EXPERIMENTAL): ZPL389 3 mg oral powder
- ZPL389 10 mg (Type: EXPERIMENTAL): ZPL389 10 mg oral powder
- ZPL389 30mg (Type: EXPERIMENTAL): ZPL389 30 mg oral powder
- ZPL389 50mg (Type: EXPERIMENTAL): ZPL389 50 mg oral powder

Based on this trial design, predict the completion outcome and termination type (if applicable).